Form 4: Neogenomics Director Elizabeth Floegel Reports Stock Option Grant and Restricted Stock Unit Award

Director Elizabeth Floegel reports acquisition of stock options and restricted stock units in Neogenomics Inc.

Summary

• On June 1, 2024, Elizabeth Floegel, a director of Neogenomics Inc., reported the acquisition of stock options and restricted stock units.
• Floegel acquired 8,672 stock options with an exercise price of $13.71, exercisable from June 1, 2025, and expiring on June 1, 2034.
• She also acquired 12,254 restricted stock units, vesting on June 1, 2025.
• Following these transactions, Floegel directly owns 8,353 stock options (exercise price $14.82, expiring August 10, 2033), 11,336 restricted stock units, 8,672 stock options (exercise price $13.71, expiring June 1, 2034), and 12,254 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and restricted stock units is a routine part of executive compensation and suggests confidence in the company's future, but it's not a major event.

Positives

• The acquisition of stock options and restricted stock units by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Companies like Exact Sciences and Guardant Health also use stock options and RSUs as part of their compensation packages for directors and executives.
• The specific amounts and vesting schedules vary based on company size, performance, and individual contributions.

Stakeholder Impact

• The granting of equity-based compensation can align the interests of the director with those of shareholders, potentially leading to increased focus on long-term value creation.

Key Dates